# Pro Dex Inc: overview PDEX · Nasdaq · CIK 788920 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/pdex.md) · [Financials](/companies/pdex/financials.md) · [Filings](/companies/pdex/filings.md) · [Insiders](/companies/pdex/insiders.md) Latest reported revenue: [$20.6m](/filings/0001079973-26-001410.md) for Q1 FY2027, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:Revenues, accession 0001079973-26-001410). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [16.8](/filings/0001079973-26-000140.md) | [17.4](/filings/0001079973-26-000580.md) | [17.5 d](/filings/0001079973-26-001215.md) | [18.5](/filings/0001079973-26-001410.md) | [18.7](/filings/0001079973-26-000140.md) | [19.9](/filings/0001079973-26-000580.md) | [20.4 d](/filings/0001079973-26-001215.md) | [20.6](/filings/0001079973-26-001410.md) | | Gross margin | % | [30.2%](/filings/0001079973-26-000140.md) | [33.3%](/filings/0001079973-26-000580.md) | [20.0% d](/filings/0001079973-26-001215.md) | [29.0%](/filings/0001079973-26-001410.md) | [30.8%](/filings/0001079973-26-000140.md) | [30.7%](/filings/0001079973-26-000580.md) | [34.8% d](/filings/0001079973-26-001215.md) | [33.4%](/filings/0001079973-26-001410.md) | | Operating margin | % | [16.0%](/filings/0001079973-26-000140.md) | [20.9%](/filings/0001079973-26-000580.md) | [7.7% d](/filings/0001079973-26-001215.md) | [16.8%](/filings/0001079973-26-001410.md) | [17.5%](/filings/0001079973-26-000140.md) | [15.5%](/filings/0001079973-26-000580.md) | [17.3% d](/filings/0001079973-26-001215.md) | [17.1%](/filings/0001079973-26-001410.md) | | Net margin | % | [12.1%](/filings/0001079973-26-000140.md) | [18.8%](/filings/0001079973-26-000580.md) | [6.8% d](/filings/0001079973-26-001215.md) | [25.3%](/filings/0001079973-26-001410.md) | [11.7%](/filings/0001079973-26-000140.md) | [19.7%](/filings/0001079973-26-000580.md) | [14.0% d](/filings/0001079973-26-001215.md) | [14.8%](/filings/0001079973-26-001410.md) | | Diluted EPS | $ per share | [0.61](/filings/0001079973-26-000140.md) | [0.98](/filings/0001079973-26-000580.md) | not reported | [1.40](/filings/0001079973-26-001410.md) | [0.66](/filings/0001079973-26-000140.md) | [1.20](/filings/0001079973-26-000580.md) | not reported | [0.92](/filings/0001079973-26-001410.md) | | Free cash flow | $m | [(4.7) d](/filings/0001079973-26-000140.md) | [0.6 d](/filings/0001079973-26-000580.md) | [(0.3) d](/filings/0001079973-26-001215.md) | [2.2](/filings/0001079973-26-001410.md) | [3.5 d](/filings/0001079973-26-000140.md) | [1.5 d](/filings/0001079973-26-000580.md) | [(0.5) d](/filings/0001079973-26-001215.md) | [6.1](/filings/0001079973-26-001410.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [42.0](/filings/0001079973-23-001429.md) | [46.1](/filings/0001553350-24-000079.md) | [53.8](/filings/0001079973-25-001426.md) | [66.6](/filings/0001079973-26-001215.md) | [77.5](/filings/0001079973-26-001215.md) | | Gross margin | % | [31.2%](/filings/0001079973-23-001429.md) | [27.7%](/filings/0001553350-24-000079.md) | [27.0%](/filings/0001079973-25-001426.md) | [29.3%](/filings/0001079973-26-001215.md) | [31.4%](/filings/0001079973-26-001215.md) | | Operating margin | % | [12.2%](/filings/0001079973-23-001429.md) | [12.5%](/filings/0001553350-24-000079.md) | [13.3%](/filings/0001079973-25-001426.md) | [16.1%](/filings/0001079973-26-001215.md) | [16.8%](/filings/0001079973-26-001215.md) | | Net margin | % | [10.9%](/filings/0001079973-23-001429.md) | [15.3%](/filings/0001553350-24-000079.md) | [4.0%](/filings/0001079973-25-001426.md) | [13.5%](/filings/0001079973-26-001215.md) | [17.6%](/filings/0001079973-26-001215.md) | | Diluted EPS | $ per share | [1.21](/filings/0001079973-23-001429.md) | [1.95](/filings/0001553350-24-000079.md) | [0.60](/filings/0001079973-25-001426.md) | [2.67](/filings/0001079973-26-001215.md) | [4.12](/filings/0001079973-26-001215.md) | | Free cash flow | $m | [(2.5)](/filings/0001079973-23-001429.md) | not reported | not reported | [(2.9)](/filings/0001079973-26-001215.md) | [6.8](/filings/0001079973-26-001215.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pdex/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $9.0m | 153,178 | | Added +663 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.8m | 82,283 | | Reduced −29,047 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $3.3m | 57,061 | | Added +120 | | [PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.](/funds/1238990.md) | 2026-06-30 | $3.1m | 52,735 | | Reduced −9,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.9m | 49,636 | | Added +1,289 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $1.9m | 32,287 | | Added +251 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.8m | 31,310 | | Reduced −1,804 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $1.1m | 18,711 | | Added +8,570 | | [Pekin Hardy Strauss, Inc.](/funds/1020317.md) | 2026-06-30 | $966.1k | 16,500 | | New +16,500 | | [BNP PARIBAS FINANCIAL MARKETS](/funds/1166588.md) | 2026-06-30 | $933.6k | 15,945 | | Added +2,711 | ## Recent filings [All 735 filings](/companies/pdex/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 16:07 ET | [8-K](/filings/0001079973-26-001415.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001079973-26-001415 | | 2026-10-29 | 16:04 ET | [8-K](/filings/0001079973-26-001411.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001079973-26-001411 | | 2026-10-29 | 16:01 ET | [10-Q](/filings/0001079973-26-001410.md) | Quarterly report, period 2026-09-30 | 0001079973-26-001410 | | 2026-10-06 | 16:01 ET | [DEF 14A](/filings/0001079973-26-001325.md) | Proxy statement, period 2026-11-19 | 0001079973-26-001325 | | 2026-09-18 | 16:00 ET | [8-K](/filings/0001079973-26-001261.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001079973-26-001261 | | 2026-09-03 | 16:11 ET | [8-K](/filings/0001079973-26-001216.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001079973-26-001216 | | 2026-09-03 | 16:09 ET | [10-K](/filings/0001079973-26-001215.md) | Annual report, period 2026-06-30 | 0001079973-26-001215 | | 2026-08-28 | 16:00 ET | [8-K](/filings/0001079973-26-001196.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001079973-26-001196 | | 2026-06-26 | 17:59 ET | [SCHEDULE 13D/A](/filings/0000897069-26-001456.md) | Ownership report, active investor, amended | 0000897069-26-001456 | | 2026-06-17 | 17:25 ET | [8-K](/filings/0001079973-26-000854.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001079973-26-000854 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001079973-26-001215.md), filed Sep 3, 2026. ## Forecast league Q1 FY2027, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/d5ced747-d974-4f9b-a439-d0d3f0893fb0) ## About the filer - CIK: 788920 - Tickers: PDEX - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:16 ET. No prices; not investment advice.